

BUY**TP: Rs 1,500 | ▲ 23%****DR REDDY'S LABS**

Pharmaceuticals

22 January 2026

ex of North America, guidance above expectations

- Sales/EBITDA/PAT reported 1.4%/0.1%-7.1%. EBITDA margin in-line, marginally 28bps below our estimates
- All regions, barring the US, to sustain double-digit growth rate in FY27E. Domestic sales growth buoyance likely to sustain
- Outlook exceeded expectations; upgrade EPS estimates by 4%, 9% and 3% for FY26E/27E/28E resp., Upgrade to BUY with 21x PE on Dec'27 EPS

Foram Parekh
 Research Analyst
 research@bobcaps.in

In-line estimates – Dr Reddy's sales were in line with our estimates, where sales grew 4.4% YoY to Rs 87bn. Growth in sales was due to 7% YoY growth in Global generics (91% contribution) to Rs 79bn offset by 2% decline in PSAI (9% contribution) to Rs 8bn and 92% decline in Proprietary products to Rs 137 mn. Global Generics' sales growth came on the back of 32% YoY growth in Emerging Markets, 20% YoY growth in Europe region and 19% YoY growth in the domestic region, offset by 12% YoY decline in the US region. During the quarter, there was very little sales from Revlimid that resulted in Global generics gross margin of 57% (59% in 2QFY26) and 17% margins (18% in 2QFY26) for PSAI segment as well as an inclusion of Rs 1,170 mn towards the New Labour Codes resulted in consolidated gross margin declining 504 bps YoY but declined only 37 bps QoQ to 53.6%. Subsequently, EBITDA Margin declined 579 bps YoY and 28 bps QoQ to 21.7% and resulted in 17.6% YoY and flattish growth in EBITDA to Rs 18.9bn. Subsequently, PAT declined by 12.5% YoY and 5% QoQ to Rs 12.3 bn in 3QFY26.

North America sales decline lower vs estimates – During the quarter, the Revlimid contribution was lower than the previous quarter, but the region saw a 12% decline in 3QFY26 (15% decline, as per our estimates) vs 13% in 2QFY26, with higher Lenalidomide sales than 3QFY26. Going forward, Lenalidomide sales is expected to be negligible and until the Semaglutide approval in Canada, we believe the company's North America base should settle around 3QFY26 base, between Rs 25 - Rs 28bn. The company also expects Semaglutide approval from Health Canada between Feb-May'26, thus being able to clock Semaglutide sales from 1QFY26. Thus, we expect North America sales to report -5% CAGR from FY26-28E.

Domestic sales to retain at-least 15% growth – During the quarter, domestic region reported growth of 19% YoY, driven primarily by the acquisition of Stugeron and in-licensed portfolio (max contribution 15% of domestic sales). The company will likely launch its first GLP product Semaglutide (Ozempic) in the domestic market on 21st March 2025, initially through partner and subsequently through backward integration. Thus, we expect domestic region to grow at 16% CAGR from FY26-28E as the newly acquired brand scales up.

Key changes

Target	Rating
▲	▲

Ticker/Price	DRRD IN/Rs 1,218
Market cap	US\$ 11.1bn
Free float	73%
3M ADV	US\$ 24.0mn
52wk high/low	Rs 1,380/Rs 1,020
Promoter/FPI/DII	27%/27%/23%


Source: NSE | Price as of 22 Jan 2026

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	325,534	344,315	352,926
EBITDA (Rs mn)	86,235	80,914	84,702
Adj. net profit (Rs mn)	58,720	51,950	54,719
Adj. EPS (Rs)	70.6	62.4	65.8
Consensus EPS (Rs)	72.0	61.6	56.6
Adj. ROAE (%)	19.5	14.6	13.5
Adj. P/E (x)	17.3	19.5	18.5
EV/EBITDA (x)	12.2	12.8	12.5
Adj. EPS growth (%)	5.5	(11.5)	5.3

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



European region to sustain double-digit growth rate with NRT sales- During the quarter, Europe region reported 20% YoY growth, driven by 26% YoY growth in NRT sales and 15% YoY growth in the sales excluding. NRT sales reported cc growth of 8% as it has completed 85% integration. We expect the cc growth rate to increase, as the company achieves 100% integration in 4QFY26. Ex of NRT, we expect sales to go up on the back of biosimilar sales and with the launch of Abatacept in the European region in ~FY28E, we believe sales excluding NRT, can report higher growth rate from the current 15%. Thus, we expect the entire Europe to grow at a CAGR of 16% YoY from FY26-28E.

Abatacept launch likely in multiple countries - The company has filed Abatacept IV version in Dec'25, as quoted and expects to receive approval by the end of CY26 without any requirement of plant inspection. The company also expects to file the Subcutaneous version by July'27 and receive approval in FY28. The company expects to launch the product in multiple markets like Europe, US and Japan, where in all the markets, Dr. Reddy's is likely to be the only generic player in the near term with European TAM of USD 2bn.

EBITDA Margin to recover in FY28E- During 3QFY26, the contribution of Lenalidomide was minimal, factoring in EBITDA margin as per expectations at 22%; while 9MFY26 EBITDA margin at 23.3%. Going forward, with Lenalidomide's contribution in the US market being zero, Global generics margins is expected to be 52-55%. However, the decline is expected to offset by lower R&D cost due to exhaustion of higher spends on Abatacept's development. Thus, with R&D cost rationalisation (not expected to increase contribution with development of Subcutaneous version) followed by GLP launch in ~87 countries from Mar'26, EBITDA margin can be content at 25% by FY28E.

Valuation - We continue to ascribe 21x on Dec'27 roll-forward EPS to arrive at TP of Rs 1,500 (earlier PT of Rs 1324), implying an upside of 23%, thereby upgrading the stock to BUY (earlier HOLD), ahead of the Semaglutide approval and CRL in biosimilars like Denosumab and Rituximab. While exclusivity period for the Semaglutide launch in Canada would be short lived, Q3 marks a base for North America region with minimal Lenalidomide and no Semaglutide at Rs 29.6mn. However, we are assuming a base of Rs 27mn on a quarterly run rate — a 7% decline on 3QFY26 quarterly run rate factoring in moderate positivity. Although the company has received CRL for biosimilars, leading to a 6-month delay for Denosumab and 1 year for Rutuximab, FY28e is likely to witness steep recovery on account of 1) lower base 2) launch of Abatacept, Rituximab and Denosumab in the North America region and 3) GLP scale up with backward integration.

Financial Highlights

Fig 1 – Quarterly highlights

(Rs mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Var (%)
Net Sales	87,268	83,586	4.4	88,051	(0.9)	86,074	1.4
Total Expenses	68,314	60,590	12.7	67,498	1.2	67,138	1.8
(%) of net sales	78.3	72.5		76.7		78	
Raw material consumed	40,462	34,534	17.2	39,911	1.4	39,594	2.2
(%) of net sales	46.4	41.3		45.3		46	
R&D cost	6,149	6,658	(7.6)	6,202	(0.9)	6,025	2.1
(%) of net sales	7.0	8.0		7.0		7	
SG&A	21,703	19,398	11.9	21,385		21,518	
(%) of net sales	24.9	23.2		24.3		25	
EBITDA	18,954	22,996	(17.6)	20,553	(7.8)	18,936	0.1
Depreciation	5,215	4,719	10.5	5,051		5,164	
EBIT	13,739	18,277	(24.8)	15,502	(11.4)	13,772	(0.2)
Interest	(1,168)	20	(5940.0)	(774)		(900)	
Other Income	770	439		2,673		2,500	
PBT	15,677	18,696	(16.1)	18,949	(17.3)	17,172	(8.7)
Less: Taxation	3,533	4,704		4,082		4,322	
Recurring PAT	12,369	14,129	(12.5)	15,034	(17.7)	13,017	(5.0)
Exceptional items	(271)	4		(662)		0	
Reported PAT	12,098	14,133	(14.4)	14,372	(15.8)	13,017	(7.1)
Key Ratios (%)							
Gross Margin	53.6	58.7	(505)	54.7	(104)	54.0	(37)
EBITDH Margin	21.7	27.5	(579)	23.3	(162)	22.0	(28)
Tax / PBT	22.5	25.2	(262)	21.5	99	25.2	(263)
NPM	14.2	16.9	(273)	17.1	(290)	15.1	(95)
Adj. EPS (Rs)	14.9	17.0	(12)	18.1	(18)	15.6	(78)

Source: Company, BOBCAPS Research

Revenue Mix


Fig 2 – Segmental Revenue

(Rs mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	Q3FY26E	Var (%)
Global generics	79,113	73,752	7.3	78,498	0.8	75,084	5.4
North America	29,644	33,834	(12.4)	32,408	(8.5)	28,759	3.1
Europe	14,476	12,096	19.7	13,762	5.2	15,030	(3.7)
India	16,032	13,464	19.1	15,780	1.6	15,214	5.4
ROW	18,961	14,358	32.1	16,548	14.6	16,081	17.9
PSAI	8,018	8,219	(2.4)	9,450	(15.2)	9,698	(17.3)
Proprietary Products	137	1,614	(91.5)	103	33.0	1,291	(89.4)
Net Sales	87,268	83,585	4.4	88,051	(0.9)	86,074	1.4

Source: Company, BOBCAPS Research


Financial Charts

Fig 3 – Total sales lowered due to the lack of Lenalidomide sales




Source: Company, BOBCAPS Research

Fig 4 – EBITDA decline on lower Global generics margins and one-time expense of New labour Cost




Source: Company, BOBCAPS Research

Fig 5 – PAT growth decreased with lower operations




Source: Company, BOBCAPS Research

Fig 6 – EBITDA margin maintained at 23% without Lenalidomide contribution




Source: Company, BOBCAPS Research

Fig 7 – North America sales lowered given the absence of Lenalidomide and price erosion



Source: Company, BOBCAPS Research

Fig 8 – Domestic sales growth rate increasing with the Stugeron-acquisition



Source: Company, BOBCAPS Research

Valuation Methodology

We raise our EPS estimates by 4%/9%/3% for FY26E, FY27E and FY28E respectively, as 1) US decline was lesser at 12% vs our estimates of 15%

2) domestic growth expected to sustain at 15% 2) Europe and Emerging Markets likely to grow in double digits 3) Rising Other income.


We continue to ascribe 21x on Dec'27 roll-forward EPS to arrive at TP of Rs 1,500 (earlier PT of Rs 1324), implying an upside of 23%, thereby upgrading the stock to BUY (earlier HOLD), ahead of the Semaglutide approval and CRL in biosimilars like Denosumab and Rituximab. While exclusivity period for the Semaglutide launch in Canada would be short lived, Q3 marks a base for North America region with minimal Lenalidomide and no Semaglutide at Rs 29.6mn. However, we are assuming a base of Rs 27mn on a quarterly run rate — a 7% decline on 3QFY26 quarterly run rate factoring in moderate positivity. Although the company has received CRL for biosimilars, leading to a 6-month delay for Denosumab and 1 year for Rutuximab, FY28e is likely to witness steep recovery on account of 1) lower base 2) launch of Abatacept, Rituximab and Denosumab in the North America region and 3) GLP scale up with backward integration.

Fig 9 – Change in Estimates

(Rs mn)	New			New			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	344,315	352,926	390,990	346,661	345,187	372,478	(1)	2	5
EBITDA	80,914	84,702	97,748	82,052	82,845	94,982	(1)	2	3
EBITDA margin (%)	23.5	24	25	23.7	24.0	25.5	(17bps)	(0bps)	(50bps)
EPS (Rs)	62.4	65.8	73.3	60	60.4	71.1	4	9	3

Source: Company, BOBCAPS Research

Fig 10 – PE Band



Source: Company, BOBCAPS Research

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	279,164	325,534	344,315	352,926	390,990
EBITDA	78,377	86,235	80,914	84,702	97,748
Depreciation	14,700	17,058	20,341	22,291	24,166
EBIT	63,677	69,177	60,573	62,411	73,582
Net interest inc./(exp.)	(1,711)	(2,829)	(1,730)	(1,838)	(2,070)
Other inc./(exp.)	9,904	11,911	10,423	12,385	9,792
Exceptional items	0	0	0	0	0
EBT	71,870	78,259	69,266	72,958	81,304
Income taxes	16,186	19,539	17,317	18,240	20,326
Extraordinary items	0	(1,476)	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	55,684	57,244	51,950	54,719	60,978
Adjustments	0	(1,476)	0	0	0
Adjusted net profit	55,684	58,720	51,950	54,719	60,978

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	30,919	35,523	37,733	38,677	42,848
Other current liabilities	49,676	53,102	48,204	42,351	46,919
Provisions	5,444	6,324	6,689	6,856	7,596
Debt funds	20,020	46,766	39,751	33,788	25,341
Other liabilities	0	0	0	0	0
Equity capital	832	832	832	832	832
Reserves & surplus	269,851	331,932	379,722	430,280	487,098
Shareholders' fund	270,683	332,764	380,554	431,112	487,930
Total liab. and equities	376,742	474,479	512,931	552,785	610,634
Cash and cash eq.	7,105	14,652	25,552	45,762	79,985
Accounts receivables	80,298	90,420	94,333	96,692	102,836
Inventories	63,552	71,085	73,580	77,354	87,839
Other current assets	28,079	33,492	41,318	49,410	54,739
Investments	79,618	58,456	58,456	58,456	58,456
Net fixed assets	76,886	97,761	104,420	107,130	107,964
CWIP	0	0	0	0	0
Intangible assets	41,204	108,613	115,272	117,982	118,816
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	376,742	474,479	512,931	552,785	610,634

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	55,590	62,973	57,464	59,881	74,734
Capital expenditures	(15,200)	(27,504)	(27,000)	(25,000)	(25,000)
Change in investments	(18,238)	21,162	0	0	0
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(33,438)	(6,342)	(27,000)	(25,000)	(25,000)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	6,548	26,746	(7,015)	(5,963)	(8,447)
Interest expenses	(1,711)	(2,829)	(1,730)	(1,838)	(2,070)
Dividends paid	(4,160)	(4,160)	(4,160)	(4,160)	(4,160)
Other financing cash flows	(21,502)	(68,841)	(6,659)	(2,709)	(834)
Cash flow from financing	(20,825)	(49,084)	(19,564)	(14,670)	(15,511)
Chg in cash & cash eq.	1,327	7,547	10,900	20,210	34,223
Closing cash & cash eq.	7,105	14,652	25,552	45,762	79,985

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	66.9	68.8	62.4	65.8	73.3
Adjusted EPS	66.9	70.6	62.4	65.8	73.3
Dividend per share	5.0	5.0	5.0	5.0	5.0
Book value per share	326.1	400.9	458.5	519.4	587.9

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	3.8	3.2	3.0	3.0	2.8
EV/EBITDA	13.6	12.2	12.8	12.5	11.1
Adjusted P/E	18.2	17.3	19.5	18.5	16.6
P/BV	3.7	3.0	2.7	2.3	2.1

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	77.5	75.0	75.0	75.0	75.0
Interest burden (PBT/EBIT)	112.9	113.1	114.4	116.9	110.5
EBIT margin (EBIT/Revenue)	22.8	21.3	17.6	17.7	18.8
Asset turnover (Rev./Avg TA)	26.4	24.3	21.5	19.9	20.0
Leverage (Avg TA/Avg Equity)	1.1	1.1	1.1	1.1	1.1
Adjusted ROAE	22.5	19.5	14.6	13.5	13.3

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	13.5	16.6	5.8	2.5	10.8
EBITDA	22.2	10.0	(6.2)	4.7	15.4
Adjusted EPS	21.7	5.5	(11.5)	5.3	11.4

Profitability & Return ratios (%)

EBITDA margin	28.1	26.5	23.5	24.0	25.0
EBIT margin	22.8	21.3	17.6	17.7	18.8
Adjusted profit margin	19.9	18.0	15.1	15.5	15.6
Adjusted ROAE	22.5	19.5	14.6	13.5	13.3
ROCE	27.8	24.2	17.8	16.9	17.0

Working capital days (days)

Receivables	105	101	100	100	96
Inventory	83	80	78	80	82
Payables	40	40	40	40	40

Ratios (x)

Gross asset turnover	1.2	1.3	1.2	1.1	1.2
Current ratio	2.1	2.2	2.5	3.1	3.3
Net interest coverage ratio	37.2	24.5	35.0	33.9	35.6
Adjusted debt/equity	(0.2)	0.0	0.0	0.0	0.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): DR REDDY'S LABS (DRRD IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.